Palobiofarma SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.palobiofarma.com
Clinical Trials
10
Active:1
Completed:8
Trial Phases
2 Phases
Phase 1:6
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (60.0%)Phase 2
4 (40.0%)Therapeutic Effect of PBF-680 in Patients With COPD
Phase 2
Completed
- Conditions
- COPD
- Interventions
- Drug: PlaceboDrug: PBF-680 10mg
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 174
- Registration Number
- NCT05262218
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Bellvitge, Barcelona, Spain
🇪🇸Hospital Clinic, Barcelona, Spain
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: PBF-1650 oral capsulesDrug: Placebo oral capsule
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 32
- Registration Number
- NCT03798236
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Study of PBF-999 in Solid Tumour Advanced Cancer
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 54
- Registration Number
- NCT03786484
- Locations
- 🇪🇸
Vall d'Hebron institute of oncology (VHIO), Barcelona, Spain
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 107
- Registration Number
- NCT03774290
- Locations
- 🇪🇸
Unitat de Pneumologia Experimental, Barcelona, Spain
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 34
- Registration Number
- NCT03773952
- Locations
- 🇪🇸
Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain
- Prev
- 1
- 2
- Next
News
No news found